Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

October 31, 2012

Conditions
Low-grade Gliomas
Interventions
DRUG

Tarceva and Rapamycin

Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.

Trial Locations (1)

20010

Children's Research Institute, Washington D.C.

All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

lead

Roger Packer

OTHER